The University of Southampton
University of Southampton Institutional Repository

High incidence of glucocorticoid-induced hyperglycaemia in inflammatory bowel disease: metabolic and clinical predictors identified by machine learning

High incidence of glucocorticoid-induced hyperglycaemia in inflammatory bowel disease: metabolic and clinical predictors identified by machine learning
High incidence of glucocorticoid-induced hyperglycaemia in inflammatory bowel disease: metabolic and clinical predictors identified by machine learning
Background: glucocorticosteroids (GC) are long-established, widely used agents for induction of remission in inflammatory bowel disease (IBD). Hyperglycaemia is a known complication of GC treatment with implications for morbidity and mortality. Published data on prevalence and risk factors for GC-induced hyperglycaemia in the IBD population are limited. We prospectively characterise this complication in our cohort, employing machine-learning methods to identify key predictors of risk.

Methods: we conducted a prospective observational study of IBD patients receiving intravenous hydrocortisone (IVH). Electronically triggered three times daily capillary blood glucose (CBG) monitoring was recorded alongside diabetes mellitus (DM) history, IBD biomarkers, nutritional and IBD clinical activity scores. Hyperglycaemia was defined as CBG ≥11.1 mmol/L and undiagnosed DM as glycated haemoglobin ≥48 mmol/mol. Random forest (RF) regression models were used to extract predictor-patterns present within the dataset.

Results: 94 consecutive IBD patients treated with IVH were included. 60% (56/94) of the cohort recorded an episode of hyperglycaemia, including 57% (50/88) of those with no history of DM, of which 19% (17/88) and 5% (4/88) recorded a CBG ≥14 mmol/L and ≥20 mmol/L, respectively. The RF models identified increased C-reactive protein (CRP) followed by a longer IBD duration as leading risk predictors for significant hyperglycaemia.

Conclusion: hyperglycaemia is common in IBD patients treated with intravenous GC. Therefore, CBG monitoring should be included in routine clinical practice. Machine learning methods can identify key risk factors for clinical complications. Steroid-sparing treatment strategies may be considered for those IBD patients with higher admission CRP and greater disease duration, who appear to be at the greatest risk of hyperglycaemia.
e000532
McDonnell, Martin
9a38a172-6b0b-4a6a-ad20-bd2de5cb0ec4
Harris, Richard J.
1d744e4f-cbe2-4bf7-b9fa-890707fcaff1
Borca, Florina
31fc3965-6bcf-4fd6-85bc-8b0f99f62473
Mills, Tilly
ed2bcc4c-ac6a-4992-90a5-1849648f4ea3
Downey, Louise
773acab1-0222-4f16-8e9f-03c2e0578e9a
Dharmasiri, Suranga
5c391f42-3441-48ab-a231-1e50bf769b80
Patel, Mayank
8259f48b-31e3-439a-9e96-f8e095b8df72
Zare, Benjamin
52f0f051-0896-453b-bc16-dc4f3abfccac
Stammers, Matt
9350205a-3938-4d75-8e86-233a38cdbb0e
Smith, Trevor R.
53e6838c-2e95-4c8f-9325-53163ab6255d
Felwick, Richard
b19f1ab6-1de4-4df6-b149-4bc337c3fcb9
Cummings, J.R. Fraser
89e8e80c-b6e8-4387-a63c-3796b5ad7e14
Phan, Hang T.T.
2811b94c-62b7-459d-9cc1-c88057008e3b
Gwiggner, Markus
af72b597-1ead-4155-a25c-0835f7e560c2
McDonnell, Martin
9a38a172-6b0b-4a6a-ad20-bd2de5cb0ec4
Harris, Richard J.
1d744e4f-cbe2-4bf7-b9fa-890707fcaff1
Borca, Florina
31fc3965-6bcf-4fd6-85bc-8b0f99f62473
Mills, Tilly
ed2bcc4c-ac6a-4992-90a5-1849648f4ea3
Downey, Louise
773acab1-0222-4f16-8e9f-03c2e0578e9a
Dharmasiri, Suranga
5c391f42-3441-48ab-a231-1e50bf769b80
Patel, Mayank
8259f48b-31e3-439a-9e96-f8e095b8df72
Zare, Benjamin
52f0f051-0896-453b-bc16-dc4f3abfccac
Stammers, Matt
9350205a-3938-4d75-8e86-233a38cdbb0e
Smith, Trevor R.
53e6838c-2e95-4c8f-9325-53163ab6255d
Felwick, Richard
b19f1ab6-1de4-4df6-b149-4bc337c3fcb9
Cummings, J.R. Fraser
89e8e80c-b6e8-4387-a63c-3796b5ad7e14
Phan, Hang T.T.
2811b94c-62b7-459d-9cc1-c88057008e3b
Gwiggner, Markus
af72b597-1ead-4155-a25c-0835f7e560c2

McDonnell, Martin, Harris, Richard J., Borca, Florina, Mills, Tilly, Downey, Louise, Dharmasiri, Suranga, Patel, Mayank, Zare, Benjamin, Stammers, Matt, Smith, Trevor R., Felwick, Richard, Cummings, J.R. Fraser, Phan, Hang T.T. and Gwiggner, Markus (2020) High incidence of glucocorticoid-induced hyperglycaemia in inflammatory bowel disease: metabolic and clinical predictors identified by machine learning. BMJ Open Gastroenterology, 7 (1), e000532. (doi:10.1136/bmjgast-2020-000532).

Record type: Article

Abstract

Background: glucocorticosteroids (GC) are long-established, widely used agents for induction of remission in inflammatory bowel disease (IBD). Hyperglycaemia is a known complication of GC treatment with implications for morbidity and mortality. Published data on prevalence and risk factors for GC-induced hyperglycaemia in the IBD population are limited. We prospectively characterise this complication in our cohort, employing machine-learning methods to identify key predictors of risk.

Methods: we conducted a prospective observational study of IBD patients receiving intravenous hydrocortisone (IVH). Electronically triggered three times daily capillary blood glucose (CBG) monitoring was recorded alongside diabetes mellitus (DM) history, IBD biomarkers, nutritional and IBD clinical activity scores. Hyperglycaemia was defined as CBG ≥11.1 mmol/L and undiagnosed DM as glycated haemoglobin ≥48 mmol/mol. Random forest (RF) regression models were used to extract predictor-patterns present within the dataset.

Results: 94 consecutive IBD patients treated with IVH were included. 60% (56/94) of the cohort recorded an episode of hyperglycaemia, including 57% (50/88) of those with no history of DM, of which 19% (17/88) and 5% (4/88) recorded a CBG ≥14 mmol/L and ≥20 mmol/L, respectively. The RF models identified increased C-reactive protein (CRP) followed by a longer IBD duration as leading risk predictors for significant hyperglycaemia.

Conclusion: hyperglycaemia is common in IBD patients treated with intravenous GC. Therefore, CBG monitoring should be included in routine clinical practice. Machine learning methods can identify key risk factors for clinical complications. Steroid-sparing treatment strategies may be considered for those IBD patients with higher admission CRP and greater disease duration, who appear to be at the greatest risk of hyperglycaemia.

Text
e000532.full - Version of Record
Download (702kB)

More information

Accepted/In Press date: 23 October 2020
Published date: 13 November 2020

Identifiers

Local EPrints ID: 478458
URI: http://eprints.soton.ac.uk/id/eprint/478458
PURE UUID: 01990044-b70c-4490-8b7c-b096813c310b

Catalogue record

Date deposited: 03 Jul 2023 16:52
Last modified: 17 Mar 2024 02:43

Export record

Altmetrics

Contributors

Author: Martin McDonnell
Author: Richard J. Harris
Author: Florina Borca
Author: Tilly Mills
Author: Louise Downey
Author: Suranga Dharmasiri
Author: Mayank Patel
Author: Benjamin Zare
Author: Matt Stammers
Author: Trevor R. Smith
Author: Richard Felwick
Author: J.R. Fraser Cummings
Author: Hang T.T. Phan
Author: Markus Gwiggner

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×